scholarly journals Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
J. David Smeijer ◽  
Donald E. Kohan ◽  
David J. Webb ◽  
Neeraj Dhaun ◽  
Hiddo J.L. Heerspink
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
Receptor Antagonists

scholarly journals Endothelin Receptor Antagonists (ERA) in Hypertension and Chronic Kidney Disease: a Rose with Many Thorns

2013 ◽  
Vol 5 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Doumas M ◽  
Athyros V ◽  
Katsiki N ◽  
Reklou A ◽  
Lazaridis A ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Digital Ulcers ◽  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
Water Reabsorption ◽  
Receptor Antagonists ◽  
Pulmonary Arterial

The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the treatment of arterial hypertension. Endothelin plays a significant role in blood pressure regulation through pronounced vasoconstriction and modulation of sodium and water reabsorption in the kidneys. Endothelin receptor antagonists have been tested in many clinical trials in patients with arterial hypertension, heart failure, pulmonary arterial hypertension, systemic sclerosis, chronic kidney disease, and diabetic nephropathy. However, the results were usually disappointing, except in pulmonary hypertension and scleroderma digital ulcers. The future of ERAs for the treatment of arterial hypertension and chronic kidney disease does not seem bright, and only the combination with other classes of antihypertensive drugs might offer a way out.

CHRONIC KIDNEY DISEASE IN Ren-2 TRANSGENIC RATS AND ITS TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS

2018 ◽  
Vol 25 (3) ◽  
pp. 162
Author(s):  
Ivana Vaněčková ◽  
Silvie Hojná ◽  
Hana Rauchová ◽  
Michaela Kadlecová ◽  
Josef Zicha
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
Transgenic Rats ◽  
Receptor Antagonists

ChemInform Abstract: 2-Aryloxycarbonylthiophene-3-sulfonamides: Highly Potent and ETA Selective Endothelin Receptor Antagonists.

ChemInform ◽  
2010 ◽  
Vol 28 (50) ◽  
pp. no-no
Author(s):  
B. RAJU ◽  
C. WU ◽  
R. CASTILLO ◽  
I. OKUN ◽  
F. STAVROS ◽  
...  
Keyword(s):  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
Receptor Antagonists

scholarly journals Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease

2021 ◽  
Author(s):  
Alberto Ortiz ◽  
Charles J Ferro ◽  
Olga Balafa ◽  
Michel Burnier ◽  
Robert Ekart ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Failure ◽  
Mineralocorticoid Receptor ◽  
Diabetic Kidney Disease ◽  
Renin Angiotensin System ◽  
Cardiovascular Death ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Diabetic Kidney

Abstract Diabetic kidney disease develops in about 40% of patients with diabetes and is the commonest cause of chronic kidney disease worldwide. Patients with chronic kidney disease, especially those with diabetes mellitus, are at high risk of both developing kidney failure and cardiovascular death. The use of renin-angiotensin system blockers to reduce the incidence of kidney failure in patients with diabetic kidney disease dates back to studies that are now 20 or more years old. During the last few years sodium-glucose co-transporter-2 inhibitors have shown beneficial renal effects in randomized trials. However, even in response to combined treatment with renin-angiotensin system blockers and sodium-glucose co-transporter-2 inhibitors, the renal residual risk remains high with kidney failure only deferred, but not avoided. The risk of cardiovascular death also remains high even with optimal current treatment. Steroidal mineralocorticoid receptor antagonists reduce albuminuria and surrogate markers of cardiovascular disease in patients already on optimal therapy. However, their use has been curtailed by the significant risk of hyperkalaemia. In The FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO-DKD) study comparing the actions of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo, finerenone reduced the progression of diabetic kidney disease and the incidence of cardiovascular events with a relatively safe adverse event profile. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of mineralocorticoid receptor antagonists, analyses the potential mechanisms involved and discusses their potential future place in the treatment of patients with diabetic chronic kidney disease.

Sign in / Sign up

Export Citation Format

Share Document